Patents by Inventor Yingyun Wu

Yingyun Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE
    Publication number: 20230293667
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and; or prevention of RSV infection.
    Type: Application
    Filed: August 10, 2022
    Publication date: September 21, 2023
    Inventors: Peter M. PUSHKO, Yingyun WU, Michael J. MASSARE, Ye LIU, Gale SMITH, Bin ZHOU
  • Modified RSV F proteins and methods of their use
    Patent number: 11446374
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: September 20, 2022
    Assignee: Novavax, Inc.
    Inventors: Peter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
  • Modified RSV F proteins and methods of their use
    Patent number: 11052146
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: July 6, 2021
    Assignee: Novavax, Inc.
    Inventors: Peter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
  • MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE
    Publication number: 20200030436
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: October 11, 2019
    Publication date: January 30, 2020
    Inventors: Peter M. PUSHKO, Yingyun WU, Michael J. MASSARE, Ye LIU, Gale SMITH, Bin ZHOU
  • Highly efficient influenza matrix (M1) proteins
    Patent number: 10544399
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: January 28, 2020
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Yingyun Wu, Michael J. Massare, Peter M. Pushko, Margaret Nathan, Thomas Kort, Robin Robinson
  • MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE
    Publication number: 20190134187
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: June 15, 2018
    Publication date: May 9, 2019
    Inventors: Peter M. PUSHKO, Yingyun WU, Michael J. MASSARE, Ye LIU, Gale SMITH, Bin ZHOU
  • HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS
    Publication number: 20190062713
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Application
    Filed: March 22, 2018
    Publication date: February 28, 2019
    Inventors: Gale SMITH, Yingyun WU, Michael J. MASSARE, Peter M. PUSHKO, Margaret NATHAN, Thomas KORT, Robin ROBINSON
  • Modified RSV F proteins and methods of their use
    Patent number: 10022437
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: July 17, 2018
    Assignee: NOVAVAX, INC.
    Inventors: Peter Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
  • Highly efficient influenza matrix (M1) proteins
    Patent number: 9951317
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: April 24, 2018
    Assignee: NOVAVAX, INC.
    Inventors: Gale Smith, Yingyun Wu, Michael J. Massare, Peter M. Pushko, Margaret Nathan, Thomas Kort, Robin Robinson
  • RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS
    Publication number: 20170319682
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: February 15, 2017
    Publication date: November 9, 2017
    Inventors: Gale SMITH, Yingyun WU, Michael MASSARE, Ye LIU
  • HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS
    Publication number: 20170253861
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Application
    Filed: October 6, 2016
    Publication date: September 7, 2017
    Inventors: Gale SMITH, Yingyun WU, Michael J. MASSARE, Peter M. PUSHKO, Margaret NATHAN, Thomas KORT, Robin ROBINSON
  • Modified RSV F proteins and methods of their use
    Patent number: 9731000
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: August 15, 2017
    Assignee: Novavax, Inc.
    Inventors: Peter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
  • Modified RSV F proteins and methods of their use
    Patent number: 9717786
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: August 1, 2017
    Assignee: Novavax, Inc.
    Inventors: Peter M. Pushko, Yingyun Wu, Michael J Massare, Ye Liu, Gale Smith, Bin Zhou
  • Modified RSV F proteins and methods of their use
    Patent number: 9675685
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: June 13, 2017
    Assignee: NOVAVAX, INC.
    Inventors: Peter Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
  • Highly efficient influenza matrix (M1) proteins
    Patent number: 9464276
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: October 11, 2016
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Yingyun Wu, Michael Massare, Peter Pushko, Margaret Nathan, Thomas Kort, Robin Robinson
  • MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE
    Publication number: 20150359872
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: August 28, 2015
    Publication date: December 17, 2015
    Inventors: Peter PUSHKO, Yingyun Wu, Michael J. Massage, Ye Liu, Gale Smith, Bin Zhou
  • RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS
    Publication number: 20150335730
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: February 27, 2015
    Publication date: November 26, 2015
    Inventors: Gale SMITH, Yingyun WU, Michael MASSARE, Ye LIU
  • HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS
    Publication number: 20150307849
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Application
    Filed: February 23, 2015
    Publication date: October 29, 2015
    Inventors: Gale SMITH, Yingyun WU, Michael MASSARE, Peter PUSHKO, Margaret NATHAN, Thomas KORT, Robin ROBINSON
  • RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS
    Publication number: 20150306207
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: February 27, 2015
    Publication date: October 29, 2015
    Inventors: Gale SMITH, Yingyun WU, Michael MASSARE, Ye LIU
  • MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE
    Publication number: 20150266930
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: June 4, 2015
    Publication date: September 24, 2015
    Inventors: Peter PUSHKO, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou